Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

UnitedHealth Group Stock (UNH) Opinions on DOJ Investigation and Sentiment Shift

None

DOJ Investigation Impact: Recent discussions on X about UnitedHealth Group (UNH) have centered on the ongoing Department of Justice investigation into Medicare billing practices. Many express deep concern over potential financial penalties that could exacerbate the stock’s significant year-to-date decline. The regulatory scrutiny has sparked widespread unease among investors.

Sentiment Shift: In a surprising turn, some on X have noted a sudden shift in sentiment, with a few pointing to recent stock price recovery and raised guidance as signs of potential stabilization. Others remain cautious, citing ongoing profitability pressures and leadership changes as lingering risks. This mixed dialogue keeps the conversation dynamic and heated.

Note: This discussion summary was generated from an AI condensation of post data.

UnitedHealth Group Insider Trading Activity

UNH Insider Trades

UnitedHealth Group insiders have traded $UNH stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $UNH stock by insiders over the last 6 months:

  • PATRICK HUGH CONWAY (Chief Executive Officer, Optum) sold 589 shares for an estimated $179,645
  • CHARLES D. BAKER sold 27 shares for an estimated $9,613

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

UnitedHealth Group Congressional Stock Trading

Members of Congress have traded $UNH stock 28 times in the past 6 months. Of those trades, 13 have been purchases and 15 have been sales.

Here’s a breakdown of recent trading of $UNH stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

UnitedHealth Group Hedge Fund Activity

We have seen 1,596 institutional investors add shares of UnitedHealth Group stock to their portfolio, and 2,124 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

UnitedHealth Group Government Contracts

We have seen $16,222,299,225 of award payments to $UNH over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

UnitedHealth Group Analyst Ratings

Wall Street analysts have issued reports on $UNH in the last several months. We have seen 14 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

  • Bernstein issued a "Outperform" rating on 10/30/2025
  • Piper Sandler issued a "Overweight" rating on 10/29/2025
  • UBS issued a "Buy" rating on 10/29/2025
  • RBC Capital issued a "Outperform" rating on 10/29/2025
  • Jefferies issued a "Buy" rating on 10/17/2025
  • Goldman Sachs issued a "Buy" rating on 10/14/2025
  • Keybanc issued a "Overweight" rating on 10/08/2025

To track analyst ratings and price targets for UnitedHealth Group, check out Quiver Quantitative's $UNH forecast page.

UnitedHealth Group Price Targets

Multiple analysts have issued price targets for $UNH recently. We have seen 18 analysts offer price targets for $UNH in the last 6 months, with a median target of $403.0.

Here are some recent targets:

  • Lance Wilkes from Bernstein set a target price of $440.0 on 10/30/2025
  • Ryan Langston from TD Cowen set a target price of $338.0 on 10/30/2025
  • Jessica Tassan from Piper Sandler set a target price of $417.0 on 10/29/2025
  • Kevin Caliendo from UBS set a target price of $430.0 on 10/29/2025
  • Ben Hendrix from RBC Capital set a target price of $408.0 on 10/29/2025
  • David Windley from Jefferies set a target price of $409.0 on 10/17/2025
  • Scott Fidel from Goldman Sachs set a target price of $406.0 on 10/14/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles